Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03938454 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT03938454 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 36 participants.
The verdict
NCT03938454, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The goal of the study was to evaluate the efficacy and safety of crizanlizumab in sickle cell disease (SCD) patients with priapism.
Interventions
- DRUG Crizanlizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2019-10-16 |
| Est. Completion | 2023-11-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03938454
The ClinicalTrials.gov registry entry for NCT03938454 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Crizanlizumab is the first listed.
NCT03938454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03938454 about?
NCT03938454 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism". The goal of the study was to evaluate the efficacy and safety of crizanlizumab in sickle cell disease (SCD) patients with priapism.
What is the current status of trial NCT03938454?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2019-10-16. Estimated completion is 2023-11-29.
What interventions are being tested in trial NCT03938454?
The interventions under investigation include: Crizanlizumab (DRUG).
Who is sponsoring clinical trial NCT03938454?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.